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Malignant glioma represents the most common primary
adult brain tumor in Western industrialized countries.
Despite aggressive treatment modalities, the median sur-
vival duration for patients with glioblastoma multiforme
(GBM), the highest grade malignant glioma, has not
improved signiﬁcantly over past decades. One promising
approachtodealwithGBMistheinactivationofproteins
essential for survival or progression of glioma cells by
means of RNA interference (RNAi) techniques. A likely
candidateforanRNAitherapyofgliomasistheinhibitor
of apoptosis protein survivin. Survivin is involved in 2
main cellular processes–cell division and inhibition of
apoptosis. We show here that stable RNAi of survivin
induced polyploidy, apoptosis, and impaired prolifer-
ation of human U343-MG, U373-MG, H4, and U87-
MG cells and of primary glioblastoma cells. Proteome
proﬁler arrays using U373-MG cells identiﬁed a novel
setofdifferentiallyexpressedgenesuponRNAi-mediated
survivin knockdown. In particular, the death receptor
TRAIL R2/DR5 was strongly upregulated in survivin-
depleted glioma cells, inducing an enhanced cytotoxic
response of allogeneic human NK cells. Moreover, an
experimental in vivo therapy using polyethylenimine
(PEI)/siRNA complexes for survivin knockdown efﬁ-
ciently blocked tumor growth of established
subcutaneous U373-MG tumors and enhanced survival
of NMRI
nu/nu mice orthopically transplanted with
U87-MG cells. We conclude that survivin is functionally
relevant in gliomas and that PEI-mediated exogenous
delivery of siRNA targeting survivin is a promising strat-
egy for glioblastoma therapy.
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I
n Western industrialized countries, malignant glioma
represents the most common primary adult brain
tumor.
1,2 Despite aggressive treatment with surgical
resection followed by radiotherapy and chemotherapy,
these tumors ultimately recur.
3–5 The median duration
of survival for patients with the highest grade malignant
glioma, glioblastoma multiforme (GBM), has not
improved signiﬁcantly over the past decades, remaining
at 12–15 months.
5 The inﬁltrative nature of the
tumor, the impracticability of optimal resection, and
the resistance to combined chemo- and radiation
therapy lead to a 5-year survival rate of ,2%.
3 This
extraordinarily high morbidity has triggered a vigorous
search for novel and more speciﬁc therapeutic
approaches.
One promising avenue to deal with glioma—in par-
ticular, with glioblastoma—is the inactivation of pro-
teins that are essential for survival or progression by
RNA interference (RNAi), ﬁnally leading to the destruc-
tion of the tumor cells. Major targets for RNAi therapy
include oncogenes and genes that are involved in angio-
genesis, metastasis, survival, anti-apoptosis, and resist-
ance to chemotherapy (for review, see Ashihara et al
6),
yet they must be carefully selected. Optimal RNAi
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tionally relevant in the tumor and, to avoid site effects,
should not be expressed at signiﬁcant levels in normal
tissues. In addition, when using a 1-target-approach,
RNAi-targets should be chosen that cannot be function-
ally compensated by other members of the same protein
family.
Among the family of inhibitor of apoptosis proteins
(IAPs), survivin has received special attention because it
is highly expressed in cancer tissues and cancer cell
lines.
7 A large comparative scale analysis of human tran-
scriptsintumorandnormaltissue identiﬁedsurvivinas1
of the 4 most highly expressed genes selectively found in
tumors.
8 Survivin is also expressed in human gliomas,
9
where increased levels of expression have been described
to correlate with higher malignancy of the tumor and,
therefore, with a poorer prognosis.
10–12 Survivin exerts
an anti-apoptotic function through its baculoviral IAP
repeats domain by binding to activated caspases.
13,14
Furthermore, an anti-apoptotic capacity of survivin
through inhibition of the second mitochondria derived
apoptosis inducing factor Smac/DIABLO
15 and of the
apoptosis inducing factor has been reported.
16 The gene
for survivin, birc5, is located in 17q25 and gives rise to
a dominant expressed isoform with a molecular weight
of 16.5 kD.
7 Survivin is periodically expressed during
the cell cycle, with peak expression in the G2 and the M
phase.
17 Interestingly, its expression is impaired by p53,
and loss of p53 function, which is often observed in
cancer,increasesbirc5transcription.
18,19Itisanticipated
that an increase in survivin steady-state levels enhances
the resistance of cancer cells to chemotherapeutic drugs
or radiation.
20 Thus far, these properties of survivin are
not unique, and RNAi-mediated knockdown of survivin
might be compensated by the upregulation of other IAP
family members, such as XIAP or cIAP, or by increased
expression of anti-apoptoticmembersof the bcl2-family,
such as bcl2 and bcl-XL. However, to date, it is widely
accepted that survivin plays an additional and unique
role in the regulation of mitotic events.
21–24 The
mitoticlocalizationofsurvivin isconsistentwiththe pro-
teins described as chromosomal passenger proteins.
23–25
Duringearlymitosis,survivinassociatesaroundchromo-
somestogetherwithitsproteinpartnersAuroraB,borea-
lin, and inner centromeric protein—in particular, at the
kinetochores in metaphase.
25 Cells with impaired func-
tion of survivin or of one of its partners due to
RNAi-mediated inhibition or expression of dominant-
negative mutants showed comparable phenotypes (ie,
disturbedsegregationofchromosomesanddefectivecyto-
kinesis).
24–27 Furthermore, the disruption of the genetic
locus of survivin was not compensated and led to an
embryonically lethal phenotype in homozygous mice.
23
We hypothesized that the selective inhibition of
glioma cells by RNAi-mediated knockdown of survivin
may represent a reasonable therapeutic strategy for the
treatment of malignant brain tumors. Therefore, we
employed retroviral shRNA expression vectors and the
nonviral delivery of siRNAs to silence survivin in
glioma cells and glioma xenografts, respectively, and
analyzed the effects. We found that survivin knockdown
led to mitotic defects and decreased cell proliferation. In
particular, an impaired long-term clonogenic survival
was noted in H4 and U373-MG as well as in primary
glioblastoma cells after knockdown of survivin. In
addition, a strong increase in death receptor TRAIL
R2/DR5 expression was detected, which rendered
glioma cells more susceptible to allogeneic human NK
cells. The treatment of immune-deﬁcient mice bearing
subcutaneous U373-MG or orthothopic U87-MG
tumors, with polyethylenimine (PEI)-complexed siRNA
against survivin resulted in a signiﬁcant decrease of
tumor growth and increased survival time, respectively,
indicating the potential of RNAi approaches for survivin
inhibition as a feasible therapeutic option in GBM.
Materials and Methods
Cell Culture, Determination of Proliferation,
and Clonogenic Survival
U373-MG is a glioblastoma/astrocytoma-derived cell
line; U343-MG, U87-MG, and H4 are glioblastoma-
derived cell lines. The cell lines were kindly provided
by H. K. Schackert (Medical Faculty, Technical
University-Dresden, Dresden, Germany). The primary
glioblastoma cell lines DD-T3, DD-T4, and
DD-HT7606 were obtained in the course of surgery of
glioblastoma patients with informed consent and
approval of the local ethics committee. Primary gliobas-
toma cells of passages 8–10 and human glioma cell lines
were maintained on poly-L-lysine coated plasticware
and in Basal Minimal Eagle medium (Invitrogen) sup-
plemented with 2 mM L-glutamine and 1% nonessential
amino acids (Biochrom). Two hundred ninety-three T
cells were human embryonic kidney cells. They were cul-
tured in Dulbecco’s modiﬁed Eagle medium containing
4.5 g/L glucose (PAA Laboratories). The medium was
supplemented with 10% heat-inactivated fetal calf
serum, 100 U/mL penicillin, and 100 mg/mL streptomy-
cin (both from Invitrogen). Primary human NK cells
were isolated using a negative depletion kit (Miltenyi
Biotech) and stimulated with NKp46/CD2 beads
(Miltenyi Biotech) and 500 IU rhIL-2 (Immunotools).
After 5 days, the NK cells were used for the experiments.
All experiments with human NK cells were approved
by the local ethical committee of the Medical Faculty
Carl Gustav Carus (Technical University-Dresden).
Expression of TRAIL and CD95 ligand was tested by
FACS analysis using speciﬁc antibodies against TRAIL
and CD95L (both BD Biosciences) and Cy3- or
FITC-coupled secondary antibodies (Dianova). Cell pro-
liferation of human glioma cells was assessed by Trypan
blue staining and counting of viable cells using a hema-
cytometer. Cells (1 × 10
5 ) were plated in triplicates on
30-mm dishes and 24 h later cells were transduced
with retroviral vectors. Twenty-four h, 72 h, and 5
days after transduction, cell numbers were determined.
Long-term survival of transduced glioma cells was
tested by plating quadruplicates of 1000 cells/dish for
every vector transduction onto 10-cm dishes. After
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primary GBM cells were stained with Giemsa, and the
number of clones was quantiﬁed. At least 2 independent
experiments were performed for each cell line. The
Student t test was used for statistical analysis.
shRNA-Retroviral Vectors and Transduction
For the transduction of DNA-sequences encoding
shRNA-molecules, the self-inactivating retroviral
Moloney murine leukemia virus backbone pRVH-1 was
used. This vector contains a H1 polymerase III promoter
for the expression of shRNA molecules in reverse
orientation. pRVH1 was digested with EcoRI and NotI
and ligated with a cytomegalovirus immediate early
promoter and enhanced green ﬂuorescent protein (EGFP)
reporter gene fragment containing appropriate restriction
sites, resulting in the vector pRVH-N1-EGFP. For some
experiments, a RVH1-puro vector was used. On the
basis of 2 previously described survivin target sequences,
DNA oligonucleotides with appropriate restriction
site overhangs shown in italic (shSurvivin #237 upper
strand: 5′-gatccccgaggctggcttcatccactttcaagagaagtggatga-
agccagcctctttttggc-3′; shSurvivin #237 bottom strand:
5′-tcgagccaaaaagaggctggcttcatccacttctcttgaaagtggat-
gaagccagcctcggg-3′;
28 shSurvivin #433 upper strand:
5′-gatccccgaattaacccttggtgaatttcaagagaattcaccaagggt-
taattctttttggc-3′, shSurvivin #433 bottom strand:
5′tcgagccaaaaagaattaacccttggtgaattctcttgaaattcaccaag-
ggttaattcggg-3′29) were synthesized (Euroﬁns MWG
Biotech), and after annealing of the single strands, the
shRNA-encoding fragment was ligated into the BglII/
SalI-restrictions sites of pRVH-N1-EGFP and pRVH-
puro, respectively. As negative control, we included a
previously described shRNA against luciferase.
30
Retroviral particles were generated as described
previously.
31 In brief, 293 T cells were cotransfected
with an expression construct for gag-pol (pHIT60), the
MoMuLV-based retroviral vectors and the vesicular sto-
matitis virus G-protein (pMD.G2). Viral supernatants
were harvested 48 and 72 h after transfection. Target
cells (10
5) cells were plated in 30-mm dishes 1 day
before transduction and were transduced with retroviral
supernatants. Transduction efﬁcacies were usually in the
range of 90%–98%, as determined by FACS-analysis of
EGFP-positivecells.Gliomacells,whichweretransduced
with pRVH1-puro vectors, were additionally selected
using 10 mg/mL puromycin (Invitrogen) for 24 h.
Indirect Immunoﬂuorescence Analysis
Cells grown on poly-L-lysine–mounted glass slides and
6-mm slices from frozen brain tissues were ﬁxated for
20 min with 4% paraformaldehyde in phosphate-
buffered saline (PBS). Samples were treated with
ice-cold permeabilization solution (0.1% sodium citrate
in PBS, 0.1% Triton X-100) for 5 min. Samples were
incubated for 1 h with a polyclonal rabbit anti-survivin
antibody (R&D Systems; dilution, 1:200) or were ana-
ylzed using a monoclonal anti rabbit Ki67 (Epitomics).
Samples were washed 3 times with PBS + 0.1% BSA
and were subsequently incubated with a secondary anti-
rabbit immunoglobulin (Ig) G, Cy3 conjugated antibody
(dilution, 1:200; Jackson IR) for 1 h. DNA counterstain-
ing was accomplished with Hoechst33342 solution
(10 mg/mL) for 5 min. Finally, the stained cells and
tissues were washed 3 times in PBS/0.1% BSA and
once in double-distilled water, prior to examination by
confocal laser scanning microscopy (Leica SP5 inverse
MP) or standard immunﬂuorescence microscopy
(Olympus IX70). The Ki67-proliferation index was cal-
culated by analyzing the average percentage of
ﬂuorescence-labeled cells in ≥14 random ﬁelds from
different sections at ×400 magniﬁcation. Statistical
analysis was performed using the Student t test.
Proteome Proﬁler Array and Western Blot Analysis
Forimmunoblotanalysis,10
5 cellsgrownin6-wellplates
were harvested in 75 mL2 × Laemmli protein sample
buffer (Sigma). Samples were subsequently boiled for
10 min and placed in an ultrasonic bath for 10 min.
Equal protein amounts of lysate fractions were loaded
onto polyacrylamide gels and, after separation, blotted
onto PVDF membranes. Subsequently, membranes were
washed 3 times for 10 min in TBS + 2% Triton X-100,
0.5% Tween 20 (TBS-TT) and another 10 min in TBS.
Themembraneswereprobedwithrabbitpolyclonalanti-
survivin (R&D Systems), and signals were developed as
described below.Forloadingcontrol,blots werestripped
and probed with a monoclonal anti-tubulin antibody
(Sigma) or a monoclonal anti GAPDH (dilution,
1:1000;Cellsignaling).Cell-cyclearrestwasinvestigated
using an anti-p21
waf/cip antibody (monoclonal rabbit;
dilution, 1:1000; Cell Signaling Technology), and induc-
tion of apoptosis was analyzed by an anti-caspase 3 anti-
body (mouse monoclonal; dilution, 1:1000; Cell
Signaling). After incubationwiththe primaryantibodies,
the membranes were washed 3 times with TBS-TT and
1 × 10 min with TBS buffer. Subsequently, the mem-
branes were incubated for 1 h with appropriate second-
ary antibodies conjugated with HRP (dilution, 1:1000;
Dako). The membranes were washed again, signals
were developed with ECLplus detection solution (GE
Healthcare), and chemoluminescence was detected in a
LAS3000 device. The effects of survivin-RNAi on
U373-MG cells were assessed by the apoptosis proteome
proﬁler kit (R&D Systems) in accordance with the
instructions of the provider. The kit allows the simul-
taneous analysis of the cell cycle, stress response, and
expression of apoptosis inhibiting proteins and of pro-
and anti-apoptotic members of the bcl-2- protein family
and proteins involved in cell cycle arrest. In brief, 6 ×
10
6 U373-MG cells were seeded in T75 culture ﬂasks
and transduced with 12 mL viral supernatants represent-
ing an multiplicity of infection of 20. Three days after
transduction, the cells were harvested, the protein con-
centration was determined, and knockdown of survivin
was conﬁrmed by immunoblotting. Subsequently,
250 mL of lysate representing 150 mg of total protein
was diluted in 1.25 mL of Array buffer 1. Arrays were
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bating the arrays in the diluted lysate at 48C overnight.
The arrays were washed 3 times using wash buffer, incu-
bated for 4 h with the detection antibody cocktail
(dilution, 1:100 in 1× array buffer 1), and after repeated
washing arrays, incubated with a
Streptavidin-HRP-solution (dilution, 1:2000). Signals
were detected using the ECLplus reagent (GE
Healthcare) and the LAS3000 device. Images were
taken for several time intervals and analyzed using
imageJ software (National Institutes of Health) and by
substracting PBS background levels (negative control)
from sample signal levels. Experiments were performed
at least twice. Statistical analysis was performed using
the Student t test.
Flow Cytometry for Cell Cycle Analysis, BrdU
Incorporation and TRAIL R2/D5 Expression
Analysis of the cell cycle and apoptosis was determined
by ﬂow cytometry (FACscan; BD Bioscienes) of propi-
dium iodide-stained cells using Cell Quest Software
(BD Biosciences). In brief, nonsynchronized cells were
washed in PBS and ﬁxed in 70% (v/v) ethanol. After
centrifugation of the cells at 600 g for 10 min at 208C,
the cell pellet was suspended in 0.5 mL of
DNA-extraction buffer (4 mM citric acid in 0.2 M
Na2HPO4; pH, 7.8). After 5 min incubation at room
temperature, the cells were spun down at 600 g. The
cells were washed once with PBS, followed by incu-
bation in PBS containing 40 mg/mL propidium iodide
(Sigma) and 200 mg/mL RNase A (Sigma) for 1 h at
room temperature in the dark. Stained nuclei were
analyzed using a Becton Dickinson FACScan (BD
Biosciences) with at least 10, 000 events/determination.
Cells that displayed propidium iodide-ﬂuorescence emis-
sions lower than the 2N-DNA peak were considered to
be apoptotic (hypodiploid) cells. FACS analysis of
TRAIL R2/DR5, Fas-L, and TRAIL expression was
accomplished using monoclonal mouse anti TRAIL
R2/D5 (Acris) and monoclonal mouse anti Fas-L and
TRAIL antibodies (both from BD Biosciences) and sec-
ondary goat anti-mouse IgG coupled to FITC.
Appropriate isotype controls were included as controls.
For DNA-synthesis analysis, cells were incubated with
10 mM of BrdU (Sigma) for 45 min. Then, cells were
harvested and spun down at 330 g for 8 min. The cell
pellets were ﬁxed in cold (2208C) 70% (v/v) ethanol
at 48C. DNA of 2 × 10
5 cells/sample were denatured
by incubation with 2 N HCl-0.5% Triton X-100 for
30 min at room temperature, followed by neutralization
with 0.1 M Na2B4O7 × 10H2O (pH8.5) for 30 min at
room temperature. Subsequently, cells were stained
with ﬂuorescein isothiocyanate-conjugated anti-BrdU
antibody (BD; dilution, 1:12.5) in PBS containing 1%
BSA and 0.3% Triton-X-100 for 45 min at room temp-
erature in the dark. DNA was counterstained using pro-
pidium iodide as described above, and gated viable cells
were measured by ﬂow cytometry. An appropriate
FITC-conjugated isotype control was included in the
analysis. Experiments were performed in triplicates
and were performed at least twice. Statistical analysis
was performed with the Student t test.
51Cr Release Assay
The ability of primary human NK cells to recognize and
kill U373-MG and H4 glioma cells upon knockdown of
survivin expression was analyzed in a
51Cr release assay.
In brief, 5 days after transduction (1 × 10
6), shLuc- or
shSurvivin #433-transduced glioma target cells were
labeled with 100 mCi of
51Cr (PerkinElmer Life
Sciences) for 1 h at 378C and then washed 4 times
with PBS. Labeled target cells were plated as triplicates
in round-bottom 96-well plates at 3 × 10
3/well and
were incubated with NK effector cells at different
effector-target (E:T) ratios for 4 h and 8 h, respectively.
Released
51Cr was determined in a beta counter
(PerkinElmer Life Sciences). Maximal and minimal
release was measured by treating labeled cells with 2%
Triton X-100 or medium alone, respectively. The
speciﬁc cytotoxicity was calculated according to the fol-
lowing formula: percent-speciﬁc lysis ¼ 100 × [(cpm
experimental release - cpm spontaneous release)/(cpm
maximum release - cpm spontaneous release)].
Tumor Growth in Nude Mice and Experimental
siRNA Therapy
Nine-week-old NMRI
nu/nu mice were obtained from the
animal facility of the University of Dresden. Mice were
held under standardized pathogen-free conditions with
ad libitum access to food and water. Experiments were
approved by the responsible local authorities according
totheGermananimalprotectionlaw.Fortheexperimen-
tal PEI/siRNA therapy of established subcutaneous
tumors, U373-MG cells (1 × 10
6 in 200 mL PBS) were
injected into the right ﬂank of the mice. After 3 weeks,
the established wild-type tumors were measured using a
digital caliper, and the mice were subdivided in 3
groups with the same mean tumor diameter. For the
experiments, we used a siRNA (siSurvivin), which
targets the same complementary mRNA sequence as the
small hairpin RNA shSurvivin #433. Chemically unmo-
diﬁed siRNAs siSurvivin (sense: 5′-gaauuaacccuuggu-
gaau(tt)-3′; antisense: 5′-auucaccaaggguuaauuc(tt)-3′)
and siLuc control (sense: 5′-cguacgcggaauacuucga(tt)-
3′; antisense: 5′-ucgaaguauuccgcgguacg(tt)-3′) were syn-
thesized, puriﬁed using HPLC (Euroﬁns MWG
Biotech), and complexed with low-molecular weight
PEI F25-LMW, as described elsewhere.
32 Every 2 days,
mice received intraperitoneal injections of 10 mg
(400 mg/kg bodyweight) PEI-complexed siRNA against
survivin or ﬁreﬂy luciferase (siLuc) in 150 mL of PBS,
starting at day 1 of treatment, for a total of 10 injections.
As additional negative control, a group of mice receiving
intraperitoneal injections of 150 mL of PBS was included
to exclude nonspeciﬁc effects of PEI on tumor growth.
Tumor sizes were measured in both directions by a
digital caliper every 2 days. After calculating the mean
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culated by the formula VTumor¼ 1/6 × p × d
3.M i c e
were killed at day 21 after the start of the PEI/siRNA
treatment, and the tumors were prepared and used for
mRNA-analysis and histology. The experiments were
performed twice, with comparable results. In total, 10
controls, 11 siLuc-treated mice, and 11
siSurvivin-treated mice were analyzed. For the exper-
imental PEI/siRNA treatment of intracranial gliomas,
westereotacticallytransplantedU87-MGcellsinaccord-
ance with the guide screw method described by
Brockmann et al.
33 Guide screws were implanted 3 days
before injection of 1 × 10
6 U87-MG glioma cells in
10 mL of PBS into the right brain hemisphere of mice.
Threedaysaftertransplantationoftumorcells,theexper-
imental siRNA therapy was started with daily stereotac-
tical injections of 2.5 mg of PEI-complexed siSurvivin
and siLuc for 10 days. Mice were killed when neurologi-
cal symptoms became apparent. The experiments were
performed twice with comparable results. In total, survi-
val of 13 siLuc-treated mice, and of 12 siSurvivin-treated
mice was monitored. Additional mice, including 4
siLuc-treated mice bearing neurological symptoms and 3
siSurv-treated mice having no neurological deﬁcits, were
killed at day 17 and brain cryoslices were used for hema-
toxylin staining, Terminal deoxynucleotidyl transferase
nick end labeling (TUNEL), and Ki67 analysis. Statistical
analysis of tumor growth and survival were performed
with the Student t test and by log-rank test, respectively.
mRNA Preparation, cDNA Synthesis, and Quantitative
(Q) Real-Time Polymerase Chain Reaction (QPCR)
Total mRNA of tumor samples was prepared using a
QiaShredder and the RNAeasy kit from Qiagen in
accordance with the instructions of the provider. cDNA
was generated using 1 mg of total mRNA, Oligo
(dT)12–15 primer (GE Healthcare), and the Omniscript
reverse-transcriptase kit (Qiagen). On the basis of the
LightCycler (LC) technology (Roche), QPCR assays
wereperformedtoquantifythemRNAexpressionofsur-
vivinandofthehousekeepinggeneb-actin.Thelevelsofa
speciﬁc PCR product were determined by the use of
TaqMan probes (b-actin-TM: 5′-6FAM-CAgCTTCA
CCACCACggCCAXT-PH; Survivin-TM: 5′-6FAM-
CCACTgCCCCACTgAgAACgAgCXT-PH). As PCR
primers, we used LC-BETA_ACTIN_FOR 5′-tca
ccgagcgcggct-3′, LC_BETA_ACTIN_REV 5′-taatgt
cacgcatttccc-3, LC_SURVIVIN_FOR 5′-gccgaggctggc
ttca-3′, and LC_SURVIVIN-REV 5′-gaagaaacactgg
gccaagtct-3′.Thelevelsofalltranscriptsweredetermined
byan ampliﬁcationprotocol consisting of a denaturation
step at 958C for 10 min, followed by 40 cycles with a
958C denaturation step for 15 s, 618C annealing for 5 s,
and a 728C extension step of 5 s. Standard curves were
generated applying dilutions over 6 log scales (10
1–
10
6) per capillary using a plasmid encoding human
b-actin and a plasmid encoding human survivin and
were used to calculate the ampliﬁcation products. All
measurements were performed with aliquots from the
same cDNA batches to guarantee standardized and com-
parable conditions. A negative control (no template) was
included in each of the PCR runs. The cDNA copy
numbers of survivin mRNAs were normalized to the
quantitative measurements of b-actin mRNA levels. All
PCR runs were repeated twice to ensure reproducibility
and reliability and were analyzed by the LC quantiﬁ-
cation software, version 3.5 (Roche). For statistical
analysis, the Student t test was used.
TUNEL Apoptosis Assay
Analysis of apoptosis in tumors was performed using
TUNEL (in situ cell death detection kit; Roche) using
the protocol recommended by the supplier. DNA coun-
terstaining was accomplished with Hoechst33342 sol-
ution. Finally, cells were washed 3 times in PBS/0.1%
BSA and once in double-distilled water prior to examin-
ation by standard immunﬂuorescence microscopy
(Olympus IX70). The apoptosis index was calculated
by analyzing the mean percentage of
BrdU-FITC-labeled cells in ≥10 random ﬁelds from
different sections at ×400 magniﬁcation. Statistical
analysis was performed using the Student t test.
Determination of Interferon (IFN)-a Serum Levels
For analysis of IFN-a levels in PEI/siRNA-treated
animals (each group contained 4 animals), serum of
C57BL/6-mice and of NMRI mice treated with
PEI-complexed survivin siRNA or luciferase siRNA,
respectively, was collected. As positive control, we
included mice intraperitoneally injected with 150 mL
(100 mg/mL) of polyinosinic-polycytidylic acid (in
0.9% NaCl in endotoxin-free H2O; Cayla InvivoGen
Europe), which is known to activate TLR3 and to
increase IFN-a levels. The blood was allowed to clot
for 2 h at room temperature and was centrifuged for
10 min at 400 × g. The aqueous phase representing the
serum was removed, diluted 1:1 and 1:2 with PBS, and
analyzed in triplicates using an IFN-a enzyme-linked
immunosorbent assay (Mu-IFN- a; PBL Biomedical
Laboratories) in accordance with the instructions of
the manufacturer.
Results
Stable Knockdown of Survivin Expression in Glioma
Cells ResultsinMitotic Defects andImpairs Glioma Cell
Growth In Vitro
Retroviral expression vectors encoding EGFP and
shRNAs targeting human survivin mRNA, or ﬁreﬂy luci-
ferase mRNA as negative control, were transduced in
glioma cell lines H4, U373-MG, U343-MG, and
U87-MG. Western blot analysis of total protein lysates
conﬁrmed survivin protein expression in all tested
gliomacelllinestreatedwithshLuciferaseandanefﬁcient
knockdown of survivin protein steady-state levels when
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shSurvivin # 433 (Fig. 1A). Indirect immunoﬂuorescence
analyses of all glioma cells with knockdown of survivin
showed impaired or lost survivin immunosignals at the
kinetochores of metaphase chromosomes, conﬁrming a
robust RNAi effect (representative images are depicted
in Fig. 1B). Because no differences in the silencing
effects of the shSurvivin #237 and #433 hairpins were
observed, we used both throughout our experiments.
The inactivation of survivin caused polyploidy in all
tested glioma cell lines, with the fastest effect after survi-
vin knockdown being observed in H4 and U373-MG
glioma cells. We therefore chose these glioma cell lines
for additional experiments. When tested by FACS analy-
sis of the cellular DNA content, the H4 and U373-MG
cells developed remarkable amounts of cells with DNA
content greater than 4N within 24 h (Fig. 1C). The frac-
tion of cells with polyploidy genomes gradually
increased over time. Notably, a time-dependent slight
but signiﬁcant increase in the fraction of apoptotic
cells bearing hypodiploid genomes was detected in
U373-MG cells treated with shSurvivin (mean + stan-
dard deviation [SD], 10.1%+2.4% at 72 h after trans-
duction) compared with shLuc-transduced controls
(mean + SD, 4.9+3.2% 72 h after transduction)
(Fig. 1C). In contrast, the H4 cells showed a signiﬁcantly
larger fraction of apoptotic cells (mean + SD, 22.3%+
4.8%) when compared to the shLuc-transduced controls
(mean + SD, 9.9%+2.1%) already at 24 h after the
shSurvivin transduction, but the apoptotic rate remained
stable for all analyzed time points thereafter (Fig. 1C).
Confocal laser-scanning microscopy using a speciﬁc
antibody for survivin conﬁrmed that the knockdown of
survivin was associated with an increase in cell size
and appearance of multiple nuclei in interphase
(Fig. 1D). We hypothesized that knockdown of survivin
in H4 and U373-MG cells led to an endoreplication
without affecting cell cycle (ie, cell-cycle arrest). In line
with this notion, Western blot analysis of p21
waf/cip
induction, which hallmarks cell-cycle arrest, was not
detected in U373 cells after knockdown of survivin
(Fig. 2A). However, we observed a weak induction of
Fig. 1. Knockdown of survivin protein expression in glioma cell lines using small hairpin RNAs #237 and #433. (A) Glioma cells lines were
transduced with retroviral pRVH-N1-EGFP vectors encoding the indicated shRNAs. Western blot analyses demonstrate efﬁcient survivin
knockdown compared to shLuc controls (shLuciferase-transduced cells). (B) Confocal laser scanning microscopy-based analysis of
representative samples show the loss of survivin immuneﬂuorescence at kinetochors of shSurvivin #433-transduced U86-MG and H4
glioma cells. In the images showing shLuciferase shRNA-treated cells, arrows indicate centromere regions of chromosomes that are
positive for survivin. In contrast, note the increased number of chromosomes in the shSurvivin #433–treated cells. Bars represent 10 mm.
(C) Analysis of the DNA content in U373-MG glioma cells and H4 glioma cells, transduced with shSurvivin #433 or control
(shLuciferase). Note the increase in cell numbers with a DNA content .2N after knockdown of survivin. Arrows depict fractions of cells
with DNA contents at 4N, 8N, and .8N. The percentage of cells containing DNA content less than the 2N peak (SubG1), representing
apoptotic cells, is indicated as well. (D) Representative pictures showing the phenotype of shSurvivin #433–treated glioma cells. Note
the increased cell size and the appearance of multiple nuclei in the survivin knockdown cells. Bars represent 25 mm.
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waf/cip in shSurvivin #433-treated H4 glioma cells.
To analyze whether this weak p21
waf/cip expression
wasable to induce acell-cycle arrestand to further inves-
tigate whether H4 and U373 bearing genomes .4N still
were able to enter S-phase BrdU incorporation assays
were performed. That H4 cells were able to arrest in
the cell cycle was conﬁrmed by incubating the cells
with doxorubicin and subsequent BrdU incorporation
analysis (Fig 2A). After analyzing the BrdU incorpor-
ation in cells with knockdown of survivin, it became
clear that the knockdown of survivin led to a 40%–
45% reduction in the fraction of BrdU-positive cells.
However, H4 and U373-MG glioma cells with DNA
contents at 4N, 8N, and higher especially did not
arrest in the cell cycle and were still able to enter
S-phase (Fig. 2B). Additional experiments demonstrated
a statistically signiﬁcant near abolishment of cell pro-
liferation in U373-MG cells and H4 compared with
the shLuc-transduced controls (Fig. 3A and B). In
particular, survivin knockdown signiﬁcantly impaired
long-term survival of U373-MG and H4 cells in a
clonogenic assay (Fig. 3C and D).
Additional experiments with primary glioblastoma
cell lines DD-T3, DD-T4, and DD-HT7606 revealed a
similarphenotypeaftersurvivinknockdown,asobserved
in permanent glioma cell lines. An induction p21
waf/cip
was not detected by Western blot analysis, neither in
untreated controls nor in shLuc- and shSurvivin-
transduced cells (Fig. 4A). However, knockdown of sur-
vivin resulted in an increase in cells having genomes
.4N (Fig. 4B). The fraction of cells bearing genomes
,2N (apoptotic cells) in the primary cell lines with
knockdown of survivin were not increased in the
DD-T3 and DD-T4 primary GBM cells compared with
shLuc controls. In contrast, we noted signiﬁcantly
increased apoptosis rates in DD-HT7606 cells upon
surivivin RNAi (mean +SD, 33.8%+3.2% 72 h
after transduction) compared with those of shLuc-
Fig. 2. Analysis of p21
waf/cip and BrdU incorporation in H4 and U373-MG cell with knockdown of survivin. (A) Western blot analysis of
p21
waf/cip induction in H4 and U373-MG cells. Cells were transduced with shSurvivin #433 and shLuc. Seventy-two h after
transduction, total cell lysates were prepared and subjected to electrophoresis. After blotting, p21
waf/cip expression was investigated. To
demonstrate equal loading, the blot was stripped and probed with an antibody against the housekeeping protein GAPDH. As positive
controls for p21
waf/cip, total protein lysates from HCT116 cells treated with nocodazole (+Noc) and doxorubicine (+Dox) were included.
Note the weak p21
waf/cip signal in H4 cells with knockdown of survivin. That the H4 cells were able to arrest the cell cycle was
demonstrated by using doxorubicin and subsequent BrdU incorporation analysis. (B) BrdU incorporation analysis of H4 and U373 cells
72 h after transduction of shSurvivin #433 and transduction with shLuc control, respectively, demonstrating that the cells did not arrest
the cell cycle at 4N, 8N, and higher. Note that cells displaying polyploidy still incorporate BrdU.
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after transduction) (Fig. 4B). Notably, we observed that
the effect of survivin knockdown on clonogenic survival
of primary glioblastoma cells was even stronger than
measured for H 4 and U373-MG cells. Here, clonogenic
survival of primary glioma cells was nearly completely
abolished after RNAi of survivin (Fig. 4C).
RNAi-Mediated Survivin Knockdown in U373-MG
Cells Induced Expression of Hypoxia Inducible Factor–
1a (HIF-1a) and of Death Receptor TRAIL R2
In addition to its function in the spindle checkpoint and
cytokinesis, survivin functions as an inhibitor of
apoptosis by blocking activated caspases and other
pro-apoptotic molecules, such as Smac/DIABLO. To
Fig. 4. Effects of survivin knockdown on primary glioblastoma
multiforme (GBM) cells. (A) Total cell lysates from hSurvivin
#433, shLuc-transduced and untreated primary GBM cells were
subjected to Western blot analysis for conﬁrming survivin
knockdown and for investigating p21
waf/cip expression. As
positive controls for p21
waf/cip, total protein lysates from HCT116
cells treated with nocodazole (+Noc) and doxorubicine (+Dox)
were included. Equal loading was demonstrated using a tubulin
antibody. (B) Analysis of the DNA content in primary
glioblastoma cell lines DD-T3, DD-T4, and DD-HT7606 either
transduced with shSurvivin #433 or control (shLuciferase). Note
the increase in cell numbers with a DNA content .2N upon
survivin knockdown. Arrows depict fractions of cells with DNA
contents at 4N and 8N. The percentage of cells containing DNA
content less than the 2N peak (SubG1), representing apoptotic
cells, is indicated as well. (C) Representative images of colony
formation assays of primary GBM cells. Cells (10
3 ) were plated
per 10-cm dish and, after 5 weeks, were stained with Giemsa.
Note the nearly completely abolished clonogenic survival of
shSurvivin #433 transduced primary GBM cells.
Fig. 3. Reduced proliferation and colony formation capacities of
U373-MG and H4 glioma cells upon knockdown of survivin. (A
and B) Proliferation of glioma cells after transduction of retroviral
vectors encoding the depicted shRNA was determined by
counting cell numbers. U373-MG (A) and H4 (B) cells transduced
with shLuciferase exhibited a time-dependent increase in cell
numbers. The numbers of U373-MG and H4 glioma cells
transduced with shSurvivin #237 and shSurvivin #433 vectors
were signiﬁcantly lower, indicating the almost absence of
proliferation (*P , .05; **P , .01). (C and D) Colony formation
of U373-MG (C) and H4 (D) glioma cells transduced as indicated
in the ﬁgure was assessed by plating of 10
3 cells per 10 cm dish
in quadruplicates. After 3 weeks cells were stained with Giemsa
and the mean+SEM number of clones was quantiﬁed. Data
represent two independent transductions (*P , .05).
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totic pathways, a proteome proﬁler analysis of
U373-MG cells was performed (for details of analyzed
proteins, see the Materials and methods section
above). Signiﬁcant alterations in protein expression on
depletion of survivin were noted as follows (marked in
the proteome proﬁler arrays in Fig. 5A) and quantiﬁed
by densitometric analysis (Fig. 5B): a marked decrease
in the survivin protein level and heat shock protein 60
(hsp60) expression, a decrease in catalase and increase
in HIF-1a expression, a decrease of the pro-apoptotic
factor BAD, a moderately but signiﬁcantly increased
expression of death receptor CD95/Fas, and a marked
upregulation of TRAIL R2/DR5. No changes in the
expression levels of p21
waf/cip and p27
kip were observed.
It was of particular interest whether survivin RNAi led
to intrinsic apoptosis via activation of effector caspase
3. As shown in Fig. 5A and in the quantitative analysis
of protein expression proﬁles (Fig. 5B), the amounts of
pro-caspase 3 and of activated caspase 3 were not
affected by survivin knockdown in our experimental
setting, compared with shLuc controls. To investigate
whether this result could be recapitulated in other
glioma cell lines, we additionally silenced survivin in
H4, U343-MG, and U87-MG cells and also found no
signals for cleaved pro-caspase 3 after RNAi of survivin
in Western blot analyses (Fig. 5C).
Increase of Cell Death Receptor TRAIL R2 Upon
Survivin Knockdown Render Glioma Cells More
Susceptible to NK Cells
Because we observed a profound increase in the
steady-state expression levels of the death receptor
TRAIL R2/DR5 in U373-MG glioma cells upon knock-
down of survivin (see Fig. 5A and B), it was of special
interest whether human immune effector cells—in par-
ticular, NK cells—show enhanced lysis of these glioma
cells. Therefore, human NK cells were prepared from
peripheral blood, expanded, and cocultured with
shRNA-treated glioma cells. The expression of CD95L
and TRAIL on activated NK cells was conﬁrmed by
FACS analysis (data not shown). In line with the
results of the proteome proﬁler assay, FACS analysis
revealed that H4, U373-MG, U343-MG, and U87-MG
cells transduced with shLuc displayed a surface
expression of the death receptor TRAIL-R2/DR5A
(Fig. 6A). Also, TRAIL-R2/DR5 expression was
further increased after knockdown of survivin, as
revealed by analysis of the mean ﬂuorescence intensities
of TRAIL-R2/DR5-stained cells (Fig. 6A and B). On the
other hand, no signiﬁcant increase in CD95/Fas levels
were noted upon survivin inhibition in H4, U373-MG,
U343-MG, and U87-MG cells (data not shown).
51Cr
release assays demonstrated that in vitro expanded and
interleukin-2 activated NK cells—in particular, at
higher effector-target ratios—showed a increased basal
cytotoxic reaction against shLuc-treated H4 and
U373-MG glioma cells (6c). Notably, the increased
surface expression of TRAIL R2/DR5 in H4 and
Fig. 5. Proteome proﬁler analysis of glioma cells upon knockdown
of survivin. (A) Total protein lysates from glioma cells transduced
with the shLuciferase-control vector versus cells transduced with
the shSurvivin #433-vector were analyzed using an apoptosis
proteome proﬁler blot. Depicted are representative images of the
chemiluminescence signals, with differences in signal intensities
between both blots showing changes in protein expression levels
upon knockdown of survivin versus shLuciferase-treatment.
Indicated in black boxes are signiﬁcant changes in the expression
levels of distinct proteins. Red boxes indicate selected proteins of
interest showing no changes in protein expression levels after
survivin knockdown. (B) Densitometric analysis of the proteome
proﬁler blots depicting those proteins with signiﬁcant changes in
mean expression levels. Also shown are the unchanged mean
expression levels of proteins involved in cell cycle arrest and
caspase 3 status. (C) Western blot analysis of glioma cell lines
transduced with shLuciferase (shLuc) and shSurvivin #433
(shSurv) revealed no signals indicating activated caspase 3. The
levels of pro-caspase 3 remained unchanged. As positive control,
H4 cells treated with 50 mm of C2 ceramide are included. *P ,
.05. **P ..01.
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niﬁcantly enhanced glioma cell lysis after incubation
with NK cells (Fig. 6C).
Therapeutic Knockdown of Survivin Attenuates Growth
of Established Subcutaneous Glioma Xenografts and
Improves Survival of Mice in an Orthotopic Glioma
Model
In a next step, we sought to set up an experimental
therapy approach using exogenously delivered siRNA
molecules targeting survivin. We employed a low-mol-
ecular weight polyethylenimine (PEI F25-LMW) to
complex and deliver siRNA targeting survivin
(siSurvivin) in NMRI
nu/nu mice bearing established sub-
cutaneous U373-MG tumors. The PEI/siRNA com-
plexes were given systemically by intraperitoneal
injectionsstartingatday1(Fig.7A).Asnegativecontrols,
weincluded groupsof tumor-bearing mice treated with a
PEI-complexed control siRNA targeting ﬁreﬂy luciferase
(siLuc)or,toexcludenonspeciﬁceffectsofthePEIcarrier
ontumor growth,treatedwithPBS. Although thetumors
of the control mice and of the siLuc-treated mice grew
substantially and with similar growth rates, tumor
growth in siSurvivin-treated mice was markedly attenu-
ated. Differences in tumor sizes between speciﬁc treat-
ment and control groups reached statistical signiﬁcance
at day 11 after start of PEI/siRNA treatment (Fig. 7A).
In line with this observation, the mean tumor masses of
excised siSurvivin-treated tumors upon termination of
the experiment at day 21 after treatment start were
lower, compared with the mean tumor mass of the PBS-
or siLuc-treated treated control mice (data not shown).
To determine intra-tumoral survivin expression levels,
QPCR analysisusingspeciﬁc primers for human survivin
and actin was performed. Due to the small sizes of the
siSurvivin-treated tumors, only 3 tumors could be ana-
lyzed in this group, and they were compared with
results for 7 siLuc-treated tumors and 7 control tumors.
Remaining tumors samples were used for histological
analysis. The analysis of survivin mRNA revealed a
.3-fold lower expression in siSurvivin-treated tumors,
compared with siLuc-treated or -untreated (PBS)
control tumors (Fig. 7B). The histological analysis of
siSurvivin-treated U373-MG tumors revealed frequently
tumor cells with enlarged nuclei and tumor cells with
multiple nuclei, whereas no such gross morphological
changes were evident in the siLuc-treated controls
(Fig. 7C; asterisk and arrowheads, respectively). In
addition, atypical metaphase ﬁgures (propeller-like
alignment of chromosomes) were detected in tumor
Fig. 6. NK cell cytotoxicity towards glioma cells upon survivin
knockdown. (A) Knockdown of survivin increases the expression
of the death receptor TRAIL R2/DR5: H4, U373-MG, U343-MG,
and U87-MG glioma cells were transduced with a
pRVH1-puro-vector encoding the indicated shRNAs. After 5 days,
cells were stained with anti-TRAIL-R2/DR5 antibodies and
measured by FACS (gray line, isotype control; black line,
sh-Luc-transduced cells stained for TRAIL-R2/DR5; gray
histogram, sh-Survivin #433-transduced cells stained for
TRAIL-R2/DR5). (B) Quantiﬁcation of TRAIL R2/DR5 expression
levels by calculating the mean ﬂuorescence intensities (MFIs)
measured in FACS. Note the depicted increase in TRAIL R2/DR5
signal intensities in the glioma cells with knockdown of survivin.
(C) Allogeneic human NK cells show increased cytotoxicity
towards glioma cells with reduced survivin expression. NK cells
were incubated with
51chromium-loaded H4 and U373-MG
glioma cells at different effector to target ratios. H4 glioma cells
were transduced with shLuc (open squares) or shSurvivin #433
(black squares). In parallel experiments, U373-MG glioma cells
transduced with shLuc (open circles) or shSurvivin #433 (black
circles) were probed against NK cells. The cytotoxic response of
NK cells was measured after 4 h and 8 h.
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No signs of inﬁltrating leukocytes were observed in any
analyzed tumor sample.
To exclude the possibility that an unspeciﬁc response
of the innate immune system accounts for the observed
anti-tumoral effects, NMRI
nu/nu and C57BL/6m i c e
were treated with PEI-complexed siLuc or siSurvivin,
respectively, and levels of serum IFN-a were measured.
In all mice, the levels of IFN-a were less than the limit
of detection, whereas in polyinosinic-polycytidylic
acid–treated C57BL/6-positive control mice, a mean
(+SD) IFN-a level of 18+0.5 pg/mL was found
(data not shown).
For a more relevant in vivo validation we tested
whether treatment of orthotopic U87-MG xenografts
with PEI-complexed siRNA targeting survivin results
in a better survival of NMRI
nu/nu mice. Three days
after transplantation of the glioma cells, mice were
treated for 10 days with daily stereotactical injections
of PEI-complexed siRNAs targeting survivin or lucifer-
ase. No toxic side effects of PEI/siRNA complexes
were observed. Analysis at day 17 after tumor cell trans-
plantation revealed smaller tumors in mice treated with
PEI/siSurvivin, compared with the control group treated
with PEI/siLuc (Fig. 8A). Concomitantly, indirect
immunoﬂuorescence analysis of survivin expression
showed decreased immunoreactivity in PEI/
siSurvivin-treated tumors versus the PEI/siLuc controls
(Fig. 8B). The analysis of the survival of the mice (ie,
the time period before the onset of neurological symp-
toms) revealed a signiﬁcant improvement of the mean
survival time for PEI/siSurvivin-treated tumor-bearing
mice (23 days) compared with the PEI/siLuc-treated
negative controls (18 days; Fig. 8C). Additional immu-
nohistochemical analysis of the tumors showed that
that siSurvivin treatment induced a 2-fold reduction in
the percentage of Ki67-positive cells, indicating loss of
proliferation capacity (Fig. 8D). The possibility that
the observed effects were due to increased apoptosis in
the siSurvivin-treated tumors was rendered unlikely
because a TUNEL assay revealed an only slight and
statistically insigniﬁcant increase in apoptosis in
siSurvivin-treated tumors (mean apoptosis index +
SD, 0.21%+0.04%) compared with siLuc-treated
tumors (mean apoptosis index+SD, 0.11%+0.09%)
(Fig. 8E).
Discussion
GBM, classiﬁed as glioma World Health Organization
grade IV, is the most frequent and malignant brain
tumor which is mostly resistant to conventional thera-
pies.
1–3 Consequently, novel therapeutic options for
the treatment of malignant gliomas are warranted.
siRNA is evolving as a promising strategy for cancer
therapy due to its high efﬁciency and speciﬁcity in block-
ing target mRNA expression.
6,34,35 For treating exper-
imental gliomas, we chose survivin as target because it
is strongly expressed in tumors and barely detected in
normal differentiated tissues.
8 Survivin expression has
also been reported in human gliomas,
9 and expression
of survivin is found in glioma- and glioblastoma-derived
cell lines.
26 Furthermore, the knockdown of survivin
cannot be fully compensated by the upregulation of
other members of the inhibitor of apoptosis family
because, beside its role in anti-apoptosis, survivin plays
a unique and pivotal role in the spindle checkpoint and
cytokinesis.
25,29
Here, we report efﬁcient knockdown of survivin
expression in glioma cell lines and primary glioma cell
lines using retrovirus-delivered shRNAs targeting survi-
vin. Glioma cells with loss of survivin developed mitotic
defects resultinginpolyploidy,andweshowed decreased
Fig. 7. Anti-tumor effects in established tumor xenografts upon
therapeutic knockdown of survivin through polyethylenimine
(PEI)–complexed siRNA. (A) U373-MG glioma cells were
subcutaneously transplanted in the right ﬂank of NMRI
nu/nu mice.
After establishment of tumors, mice were randomized and
treated every second day by intraperitoneal injection of (i)
PEI-complexed, survivin-speciﬁc siRNA (siSurv; n ¼ 11) or, as
negative controls, (ii) PEI-complexed unrelated siRNA (ﬁreﬂy
luciferase, siLuc; n ¼ 11) or (iii) PBS (n ¼ 10). The mean+
standard error of the mean (SEM) of tumor volumes is shown at
the indicated time points after treatment start. The treatment
with PEI-complexed siSurvivin signiﬁcantly attenuates tumor
growth, with statistical signiﬁcance (*P , .05) being reached 10
days after treatment start at day 1. (B) Quantitative real-time
polymerase chain reaction analysis of survivin expression levels in
tumors of control mice (n ¼ 7) and of mice treated with
PEI-complexed siSurv (n ¼ 3) and siLuc (n ¼ 7). The mean+SEM
of survivin transcript levels is shown. *P , .05. **P , .01. (C)
Hematoxylin-eosin staining of tumor cryosections reveal
multinuclear cells (arrowheads) and huge nuclei (asterisks) in
siSurvivin-treated tumors. Also note the atypical propeller-like
mitotic ﬁgure (arrow) in the siSurvivin-treated tumor.
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term cell culture assays. In vitro analyses of the hypodi-
ploid cell fraction in U373-MG and H4 glioma cells
and primary glioma cells revealed, in most cases,
increasesinthefractionofapoptoticcells.However,pro-
teome proﬁler arrays of survivin-shRNA–transduced
U373-MG cells, and additional Western blot analysis of
U373-MG, U343-MG, U87-MG, and H4 cells after
survivin knockdown showed no activation of the
executioner caspase 3, indicating a caspase-independent
cell death mechanism. This observation is in line with
ﬁndings from other reports that describe a
caspase-independent induction of cell death upon silen-
cing of survivin or upon ectopic expression of dominant-
negative survivin mutants.
16,26,36 However, some
reports—in particular, those that used U251-MG
glioma cells—also have described a caspase-dependent
cell death upon RNAi of survivin.
37–39 Thus far, it is
tempting to speculate whether the observed differences
are cell type speciﬁc or are due to technical differences.
Survivin knockdown also resulted in a marked
decrease of hsp60. Interestingly, this chaperone mol-
ecule has been reported to directly interact with survi-
vin,
40 and RNAi-mediated reduction of hsp60 has
been reported to decrease survivin expression, in par-
ticular mitochondrial survivin levels.
40 Our data
suggests that, vice versa, hsp60 levels are dependent on
to survivin expression. Therefore, additional studies
are warranted to elucidate this survivin/HSP60 inter-
play. Moreover, we noted a decrease in catalase
expression and increase in expression of HIF-1a in
survivin-knockdown cells. These changes in protein
Fig. 8. Intracranially administered polyethylenimine (PEI)–complexed siRNA targeting survivin attenuates cellular proliferation and improves
survival of mice in an orthotopic glioma model. (A) Images showing hematoxylin-eosin–stained slices of U87-MG intracranial tumors 17
days after tumor cell transplantation. Tumors are indicated by arrowheads. Note the prominent U87-MG tumor in the siLuc treated
mouse and the smaller tumor size in siSurvivin-treated mouse. (B) Indirect immunﬂuorescence analysis using anti-survivin antibody
showing decreased survivin immunosignals in siSurvivin-treated tumors. (C) Kaplan-Meier-plot showing the time schedule of PEI/siRNA
injections and the survival curves of the animals in the different treatment groups. Mice treated with PEI/siSurvivin showed signiﬁcantly
increased survival times when compared to the PEI/siLuc-treated controls. (D) Indirect immunoﬂuorescence analysis of the proliferation
marker Ki67 reveals attenuated cell proliferation in siSurvivin-treated U87-MG cells when compared to siLuc controls (**P , .01).
Arrowheads depict the borderline between U87-MG tumor and mouse brain parenchyma. (E) Investigation of apoptosis using TUNEL
assay. Arrowheads depict apoptotic cells. No signiﬁcant increased apoptosis was detected in tumors treated with siSurvivin. A
DNase-treated slice is included as positive control. DNA counterstaining in all ﬂuorescence images were accomplished with Hoechst
33342. Bars in panel B represent 300 mm; bars in panels D and E represent 200 mm.
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of huge multinuclear cells, and we suggest that this
ﬁnding might reﬂect some adaptation of the cells to
altered intracellular reactive oxygen species and
oxygen levels.
Interestingly, we found no increase in the levels of
p21
waf/cip and p27
kip after RNAi of survivin in a pro-
teome proﬁler array, indicating that the U373-MG
glioma cells did not activate cell-cycle checkpoints. In
addition, no cell-cycle arrest was detected when analyz-
ing the DNA content of H4 cells and of 3 primary glio-
blastoma cell lines. In line with this, BrdU incorporation
assays revealed that U373-MG and H4 cells, even with
DNA contents of ≥4N, still entered S-phase. We
assume that a compromised checkpoint function
allowsongoingDNA replicationswithout the separation
of daughter cells due to defects in cytokinesis.
24 The
higher DNA contents in turn might result in prolonged
cell cycle phases, which could explain the general
decrease in the fraction of BrdU-positive cells observed
in our experiments (see Fig. 2).
The knockdown of survivin led to a downregulation
of the pro-apoptotic Bad molecule, whereas higher
expression of the death receptor CD95/Fas and an
even more pronounced increase in the steady-state
expression level of the death receptor TRAIL R2/DR5
was observed. The induction of TRAIL R2/DR5 after
RNAi-mediated targeting of survivin was veriﬁed using
FACS-based analysis of H4, U343-MG, U373-MG,
and U87-MG glioma cells. Interestingly, the increased
expression of TRAIL R2/DR5 rendered H4 and
U373-MG cells more susceptible to NK cells, as shown
in a cytotoxic assay.
Several groups have demonstrated strong anti-cancer
effects in vivo upon RNAi-mediated survivin knock-
down. However, because of problems in pharmakoki-
netics and cellular uptake of RNAi effector molecules,
siRNAs/shRNAs or shRNA-encoding vectors, most
studies were based on tumor cells transfected with
siRNAs or shRNA-encoding vectors ex vivo prior to
transplantation and in vivo analysis. Using this
approach, anti-tumoral effects were shown in xenografts
established from in vitro-transfected esophageal squa-
mous carcinoma,
41 gastric cancer,
42 pancreatic
cancer,
43 breast cancer,
44 cervical carcinoma,
44 and
glioma cells.
38 On the other hand, only a few studies
on the RNAi-mediated knockdown of survivin in
already established tumors have been reported. One
simple treatment approach made use of direct intratu-
moral injection of a shRNA-expression vector targeting
survivin mRNA. In this study, a reduction of xeno-
grafted rhabdomyosarcoma tumor growth was
observed.
45 More recently George et al.
39 reported atte-
nuated growth of orthotopic U251-MG gliomas when
stereotactically transfected with an DNA plasmid encod-
ing a shRNA targeting survivin. Other reports have
described antitumor effects in xenografted hepatocellu-
lar carcinoma, colorectal carcinoma, and non-small
cell lung carcinoma upon the delivery of
shRNA-encoding constructs against survivin using ade-
noviral vectors and replication defective lentiviral
vectors.
46–48 Likewise, an anti-cancer effect on subcu-
taneous U251-MG glioma xenografts upon direct intra-
tumoral injection of adenoviral vectors encoding a
survivin-speciﬁc shRNA has been reported.
37
However, because the in vivo delivery of
shRNA-encoding plasmids is mostly ineffective, and
because application of viral shRNA delivery systems in
patients is generally hampered due to safety concerns
and limited routes of application, we performed a thera-
peutic knockdownof survivin using a nonviral,polymer-
based carrier system for systemic siRNA delivery.
Previously, certain PEIs have been established as
reagents for complexation and cellular delivery of
siRNA in vitro and in vivo.
49–51 This siRNA delivery
platform allowed the systemic application of unmodiﬁed
siSurvivin siRNA molecules ata dose of 400 mg/kg body
weight for an experimental therapy of subcutaneous
glioma xenografts. More speciﬁcally, we demonstrate
that treatment of established U373-MG subcutaneous
xenografts using PEI-complexed siRNA targeting survi-
vin led to a decrease of survivin mRNA levels in tumors
and resulted in markedly attenuated tumor growth. The
analysis of serum samples obtained from PEI/
siRNA-treated immunodeﬁcient NMRI
nu/nu,a sw e l la s
immune-competent C57BL/6 mice, did not reveal any
IFN response, indicating that the PEI/siRNA treatment
of mice did not activate the innate immune system.
Notably, the histological investigation of the
siSurvivin-treated tumors revealed an increase in the
appearance cells bearing large nuclei, as well as
increased numbers of cells having multiple nuclei, both
being frequently observed phenotypes caused by inter-
ference with survivin function.
24,28,45,52 In connection
with our QPCR data demonstrating decreased survivin
expression levels in the siSurvivin-treated glioma xeno-
grafts,wedemonstratethat the intraperitoneally injected
PEI/siRNA complexes are able to reach the subcu-
taneous glioma xenografts, as shown elsewhere,
50 and
that PEI/siRNA-mediated survivin knockdown exerts
profound antitumor effects.
We further extended our studies toward more aggres-
sively proliferating U87-MG cells in an orthotopic
glioma model. Because the brain is an “immune privi-
leged” organ lacking the components of the lymphatic
system, a systemic delivery of siRNA to the tumor can
be envisioned only via the bloodstream. However, prob-
ably because of the blood-brain barrier, previous studies
on the biodistribution of PEI F25-LMW/siRNA after
intraperoneal injection revealed only very little siRNA
uptake into the brain. The same study showed that intra-
venous injection of PEI/siRNA-complexes via the tail
vein resulted in siRNA accumulation, mostly in the
liver and lungs.
32 These ﬁndings are in line with results
from other groups demonstrating that the transport of
nanoparticles across the blood-brain barrier will
strongly rely on ligand-mediated, “targeted” delivery
strategies or “Trojan horse” concepts (for review see
Schulze et al.
53). Despite the possibility of a somewhat
leakier blood-brain barrier, this may also apply to glio-
blastomas. Therefore, we performed a local PEI/
siRNA-treatment of orthotopic U87-MG gliomas that
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evance of this approach is supported by many clinical
studies that focused on glioma treatment and used
local delivery methods of compounds such as paclitaxel,
IL13-PE38QQR, or TGF-b2 antisense.
54–56 In the long
run, however, we and others aim to develop of ligand-
functionalized nanoparticles for the targeted delivery
of nucleic acids, allowing systemic administration and
leading to higher efﬁcacy. In summary, by applying con-
secutive stereotactical injections of PEI-complexed
siRNA targeting survivin at the tumor site, we signiﬁ-
cantly improved the survival time of mice. Additional
analysis of the proliferation marker Ki67 revealed that
siSurvivin-treated intracranial U87-MG tumors had a
decreased proliferation capacity, whereas induction of
apoptosis was barely visible.
In conclusion, our results show— to our knowledge,
for the ﬁrst time—that the knockdown of survivin
expression by exogenous, nonviral delivery of
PEI-complexed siRNA molecules signiﬁcantly inhibits
the growth of established gliomas in vivo. Our in vitro
and in vivo data indicate that loss of survivin leads to
defective mitosis and increased endoreplication in
tumor cells, ﬁnally leading to decreased proliferation
and mitotic catastrophe. Notably, glioma cells with sur-
vivin knockdown also displayed signiﬁcantly more
TRAIL R2/DR5 on the cell surface, which increased
the cytotoxic responses of human NK cells in vitro.
However, because we used immunodeﬁcient NMRI
nu/
nu mice as host for the xenografts, an appropriate
immune response in vivo appears unlikely in our exper-
iments; in line with this assumption, the histological
analysis of glioma xenografts revealed no inﬁltration of
leukocytes (ie, NK cells present in immunodeﬁcient
NMRI
nu/nu) into the treated tumors. This indicates
that the antitumor effects of PEI/siSurvivin treatment
observed here are only based on “direct” intracellular
effects of survivin knockdown. In contrast, an exper-
imental PEI/siSurvivin therapy approach targeting
transplanted syngeneic glioma cells in
immunocompetent mice will address the question
whether the host immune system can even further
promote anti-glioma effects caused by the knockdown
of survivin. However, for the development of a systemic
PEI/siRNA-therapy of gliomas, additional improve-
ments of PEI-siRNA carrier molecules are warranted.
Modiﬁcations might include covalent coupling of
maltose- or polyethylenglycol molecules for minimizing
unspeciﬁc uptake and additional conjugation of anti-
bodies (ie, transferrin receptor antibody) and ligands
(ie, transferrin, lactoferrin), which hold promise for a
receptor-mediated transcytosis in brain endothelial
cells.
57–59
In the view of the efﬁciency and speciﬁcity of RNA
interference in connection with the development of
advanced carrier systems, siRNA therapies for the
knockdown of target genes, such as survivin, may be
useful in therapy of gliomas and other cancers.
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